RS63093B1 - Terapija matičnim ćelijama kod patoloških stanja endometrijuma - Google Patents

Terapija matičnim ćelijama kod patoloških stanja endometrijuma

Info

Publication number
RS63093B1
RS63093B1 RS20220339A RSP20220339A RS63093B1 RS 63093 B1 RS63093 B1 RS 63093B1 RS 20220339 A RS20220339 A RS 20220339A RS P20220339 A RSP20220339 A RS P20220339A RS 63093 B1 RS63093 B1 RS 63093B1
Authority
RS
Serbia
Prior art keywords
bmdsc
subject
endometrial
isolated
cells
Prior art date
Application number
RS20220339A
Other languages
English (en)
Serbian (sr)
Inventor
Carlos Simon
Javier Santamaria
Antonio Pellicer
Irene Cervello
Original Assignee
Asherman Therapy S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asherman Therapy S L U filed Critical Asherman Therapy S L U
Publication of RS63093B1 publication Critical patent/RS63093B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
RS20220339A 2014-06-17 2015-06-05 Terapija matičnim ćelijama kod patoloških stanja endometrijuma RS63093B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013121P 2014-06-17 2014-06-17
EP19169309.2A EP3569697B8 (en) 2014-06-17 2015-06-05 Stem cell therapy in endometrial pathologies

Publications (1)

Publication Number Publication Date
RS63093B1 true RS63093B1 (sr) 2022-04-29

Family

ID=54329860

Family Applications (3)

Application Number Title Priority Date Filing Date
RS20220339A RS63093B1 (sr) 2014-06-17 2015-06-05 Terapija matičnim ćelijama kod patoloških stanja endometrijuma
RSP20190913 RS59210B1 (sr) 2014-06-17 2015-06-05 Terapija matičnim ćelijama kod patoloških stanja endometrijuma
RS20240690A RS65719B1 (sr) 2014-06-17 2015-06-05 Terapija matičnim ćelijama kod patoloških stanja endometrijuma

Family Applications After (2)

Application Number Title Priority Date Filing Date
RSP20190913 RS59210B1 (sr) 2014-06-17 2015-06-05 Terapija matičnim ćelijama kod patoloških stanja endometrijuma
RS20240690A RS65719B1 (sr) 2014-06-17 2015-06-05 Terapija matičnim ćelijama kod patoloških stanja endometrijuma

Country Status (22)

Country Link
US (1) US11129851B2 (https=)
EP (3) EP4012023B1 (https=)
JP (2) JP6920062B2 (https=)
CN (2) CN107073040A (https=)
AU (1) AU2015275798B2 (https=)
BR (1) BR112016029558A2 (https=)
CA (1) CA2952559C (https=)
CY (2) CY1122615T1 (https=)
DK (2) DK3569697T3 (https=)
ES (3) ES2983444T3 (https=)
HR (3) HRP20240798T1 (https=)
HU (3) HUE044823T2 (https=)
LT (2) LT3569697T (https=)
MX (1) MX377300B (https=)
PL (3) PL3569697T3 (https=)
PT (2) PT3569697T (https=)
RS (3) RS63093B1 (https=)
RU (1) RU2725006C2 (https=)
SI (2) SI3158057T1 (https=)
SM (3) SMT201900400T1 (https=)
TR (1) TR201910410T4 (https=)
WO (1) WO2015193737A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR101872965B1 (ko) 2012-10-12 2018-06-29 인바이오모션 에스.엘. Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
CA2903306A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of metastatic cancer
US11129851B2 (en) 2014-06-17 2021-09-28 Igenomix S.L. Stem cell therapy in endometrial pathologies
JP7637323B2 (ja) * 2016-06-23 2025-02-28 ティソン バイオテック，インコーポレイテッド 副甲状腺ホルモン１型受容体を発現する細胞およびその使用
RU2699029C1 (ru) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке
RU2741621C1 (ru) * 2020-09-25 2021-01-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения внутриматочных синехий
WO2023003130A1 (ko) 2021-07-23 2023-01-26 차의과학대학교 산학협력단 분리된 미토콘드리아를 유효성분으로 포함하는 아셔만 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE140868T1 (de) 1989-05-05 1996-08-15 North Sydney Area Health Serv Steigerung der fruchtbarkeit
US6979533B2 (en) 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
CA2203718A1 (en) 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
AU2001240096A1 (en) 2000-03-08 2001-09-17 Rebecca L. Dubowy Methods of diagnosing and monitoring endometrial glandular development
AU2001264900A1 (en) 2000-05-24 2001-12-03 Schering Aktiengesellschaft Pharmaceutical use of fibulin-1
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
DE10139874A1 (de) 2001-08-10 2003-04-30 Schering Ag Humane Mater-Proteine
GB0201284D0 (en) 2002-01-21 2002-03-06 Isis Innovation Screening methods for contraceptive and fertility agents
US20030186300A1 (en) 2002-03-20 2003-10-02 Ali Akoum Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions
EP1511863A4 (en) 2002-05-14 2006-12-27 Univ Leland Stanford Junior ENDOMETRIAL GENES FOR THE DETECTION OF ENDOMETRIAL DISORDERS
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ES2273061T3 (es) 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
US20060292567A1 (en) 2002-12-21 2006-12-28 Universitat Leipzig Method and means for determining specific conditions or changes in the uterine epithelium and in the epithelium of other organs
US20060286555A1 (en) 2003-08-21 2006-12-21 Van Beuningen Marinus G J Microarray support for bioprobe synthesis
WO2005026324A2 (en) 2003-09-08 2005-03-24 The Board Of Regents Of The University Of Texas System Method and composition for enhancing in vitro embryo development by supplementing culture medium with prostaglandin or a prostaglandin analog
CN1863905A (zh) 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
CA2550900A1 (en) 2003-12-23 2005-07-07 Mount Sinai Hospital Methods for detecting markers associated with endometrial disease or phase
EP1765083A4 (en) 2004-05-28 2008-08-20 Serono Lab USE OF IL-17 TO TREAT FERTILITY DISORDERS
JP2009531705A (ja) * 2006-03-31 2009-09-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 超短ｔ２＊緩和測定法を用いた細胞測定のためのシステムおよび方法
JP2007278750A (ja) 2006-04-04 2007-10-25 Ono Pharmaceut Co Ltd プロスタグランジン類及びその類縁体の定量方法
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US9259233B2 (en) * 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013166281A1 (en) * 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
EP2348318A1 (en) 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
EP2768976B1 (en) 2011-10-21 2018-01-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for assessing endometrial receptivity of a patient after controlled ovarian hyperstimulation
US9423402B2 (en) 2011-11-30 2016-08-23 Singapore Health Services Pte. Ltd. GM1 ganglioside to annexin V microparticle polypeptide ratio for biological monitoring
MX356775B (es) 2012-06-27 2018-06-13 Hoffmann La Roche Medios y metodos que aplican sflt-1/plgf o relacion de endoglina/plgf para descartar el inicio de preeclampsia en un determinado periodo de tiempo.
RU2515475C1 (ru) 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
JP6684263B2 (ja) 2014-03-21 2020-04-22 アイジェノミクス エセ．エレ． 子癇前症の早期検出
US11129851B2 (en) 2014-06-17 2021-09-28 Igenomix S.L. Stem cell therapy in endometrial pathologies

Also Published As

Publication number Publication date
CN107073040A (zh) 2017-08-18
TR201910410T4 (tr) 2019-08-21
ES2736117T3 (es) 2019-12-26
AU2015275798A1 (en) 2017-02-02
US11129851B2 (en) 2021-09-28
SI3158057T1 (sl) 2019-10-30
HRP20220419T1 (hr) 2022-05-27
PT3158057T (pt) 2019-07-19
LT3158057T (lt) 2019-09-25
RS65719B1 (sr) 2024-08-30
HRP20240798T1 (hr) 2024-09-27
CY1125938T1 (el) 2024-02-16
PT3569697T (pt) 2022-05-02
EP3158057B1 (en) 2019-04-17
EP4012023B1 (en) 2024-05-15
CN116747241A (zh) 2023-09-15
EP3569697A1 (en) 2019-11-20
JP6920062B2 (ja) 2021-08-18
DK3158057T3 (da) 2019-07-29
BR112016029558A2 (pt) 2017-08-22
EP3158057A1 (en) 2017-04-26
WO2015193737A1 (en) 2015-12-23
JP2020138984A (ja) 2020-09-03
JP2017522288A (ja) 2017-08-10
RU2725006C2 (ru) 2020-06-29
HUE067463T2 (hu) 2024-10-28
CA2952559A1 (en) 2015-12-23
AU2015275798B2 (en) 2021-03-25
PL4012023T3 (pl) 2024-09-02
EP4012023C0 (en) 2024-05-15
CY1122615T1 (el) 2021-03-12
EP3569697B1 (en) 2022-01-05
EP4012023A1 (en) 2022-06-15
MX2016016756A (es) 2017-11-02
HUE044823T2 (hu) 2019-11-28
SI3569697T1 (sl) 2022-05-31
RS59210B1 (sr) 2019-10-31
RU2017101147A3 (https=) 2019-02-06
MX377300B (es) 2025-03-07
SMT202200155T1 (it) 2022-05-12
ES2983444T3 (es) 2024-10-23
ES2910306T3 (es) 2022-05-12
LT3569697T (lt) 2022-04-25
PL3569697T3 (pl) 2022-07-04
US20170128492A1 (en) 2017-05-11
EP3569697B8 (en) 2022-04-27
SMT202400270T1 (it) 2024-07-09
CA2952559C (en) 2023-01-24
HRP20191240T1 (hr) 2019-11-01
DK3569697T3 (da) 2022-04-04
PL3158057T3 (pl) 2020-05-18
HUE058328T2 (hu) 2022-07-28
RU2017101147A (ru) 2018-07-17
SMT201900400T1 (it) 2019-09-09

Similar Documents

Publication Publication Date Title
CA2952559C (en) Stem cell therapy in endometrial pathologies
Gharibeh et al. Cell-based therapy in thin endometrium and Asherman syndrome
Lee et al. Effect of autologous adipose-derived stromal vascular fraction transplantation on endometrial regeneration in patients of Asherman’s syndrome: a pilot study
Zhang et al. Using 17β‐estradiol heparin‐poloxamer thermosensitive hydrogel to enhance the endometrial regeneration and functional recovery of intrauterine adhesions in a rat model
Gao et al. Uterine artery embolization followed by dilation and curettage within 24 hours compared with systemic methotrexate for cesarean scar pregnancy
Chang et al. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization
Hu et al. Cyclical endometrial repair and regeneration: molecular mechanisms, diseases, and therapeutic interventions
Puente Gonzalo et al. Intrauterine infusion of platelet-rich plasma for severe Asherman syndrome: a cutting-edge approach
Zhang et al. A stem cell-derived ovarian regenerative patch restores ovarian function and rescues fertility in rats with primary ovarian insufficiency
de Miguel‐Gómez et al. Strategies for managing Asherman's syndrome and endometrial atrophy: since the classical experimental models to the new bioengineering approach
Wu et al. VitroGel-loaded human MenSCs promote endometrial regeneration and fertility restoration
HK40075844A (en) Stem cell therapy in endometrial pathologies
HK40075844B (en) Stem cell therapy in endometrial pathologies
HK40099394A (zh) 子宫内膜病理状况中的干细胞治疗
HK1242600A1 (en) Stem cell therapy in endometrial pathologies
Dong Administration of i-PRF Improved Repair of Thin Endometrium via Mitochondrial Transfer
Ventura et al. Advanced Cell Therapy for Asherman's Syndrome
de Miguel Gómez et al. Stem Cell Transplantation for Endometrial Regeneration in Humans
Amer et al. Organic Tissue Grafts Following Intrauterine Adhesiolysis
Delis AMD3100 Administration for the Treatment of Asherman’s Syndrome in a Murine Model
Santamaria et al. Hysteroscopy and Stem Cell Therapy to Approach Refractory Asherman’s Syndrome
Igboeli et al. CASE REPORT Open Access
Smirnow et al. Recellularization of bovine allantochorionic blood vessels
Seifer et al. Stem cell therapies for atrophic endometrium and Asherman's syndrome
Shankar et al. Role of Low-dose Human Chorionic Gonadotropin in Follicular Phase for Thin Endometrium in Frozen Embryo Replacement Cycles in in vitro Fertilization/Intracytoplasmic Sperm Injection Patients: A Pilot Study